JP Morgan Initiates Coverage On Neurogene with Overweight Rating, Announces Price Target of $60

JP Morgan analyst Priyanka Grover has initiated coverage on Neurogene (NASDAQ: NGNE) with an Overweight rating. The firm has set a price target of $60 for the company's stock.